References

ACS (American Cancer Society). 2012. Cancer facts and figures 2012. Atlanta, GA: American Cancer Society.

Ashley, E. A., A. J. Butte, M. T. Wheeler, R. Chen, T. E. Klein, F. E. Dewey, J. T. Dudley, K. E. Ormond, A. Pavlovic, A. A. Morgan, D. Pushkarev, N. F. Neff, L. Hudgins, L. Gong, L. M. Hodges, D. S. Berlin, C. F. Thorn, K. Sangkuhl, J. M. Hebert, M. Woon, H. Sagreiya, R. Whaley, J. W. Knowles, M. F. Chou, J. V. Thakuria, A. M. Rosenbaum, A. W. Zaranek, G. M. Church, H. T. Greely, S. R. Quake, and R. B. Altman. 2010. Clinical assessment incorporating a personal genome. Lancet 375(9725):1525-1535.

Atherly, A. J., and D. R. Camidge. 2012. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer 106(6):1100-1106.

Balak, M. N., Y. Gong, G. J. Riely, R. Somwar, A. R. Li, M. F. Zakowski, A. Chiang, G. Yang, O. Ouerfelli, M. G. Kris, M. Ladanyi, V. A. Miller, and W. Pao. 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research 12(21):6494-6501.

Ball, M. P., J. V. Thakuria, A. W. Zaranek, T. Clegg, A. M. Rosenbaum, X. Wu, M. Angrist, J. Bhak, J. Bobe, M. J. Callow, C. Cano, M. F. Chou, W. K. Chung, S. M. Douglas, P. W. Estep, A. Gore, P. Hulick, A. Labarga, J. H. Lee, J. E. Lunshof, B. C. Kim, J. I. Kim, Z. Li, M. F. Murray, G. B. Nilsen, B. A. Peters, A. M. Raman, H. Y. Rienhoff, K. Robasky, M. T. Wheeler, W. Vandewege, D. B. Vorhaus, J. L. Yang, L. Yang, J. Aach, E. A. Ashley, R. Drmanac, S. J. Kim, J. B. Li, L. Peshkin, C. E. Seidman, J. S. Seo, K. Zhang, H. L. Rehm, and G. M. Church. 2012. A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America 109(30):11920-11927.

Basu, A., and D. Meltzer. 2007. Value of information on preference heterogeneity and individualized care. Medical Decision Making 27(2):112-127.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 73
References ACS (American Cancer Society). 2012. Cancer facts and figures 2012. Atlanta, GA: American Cancer Society. Ashley, E. A., A. J. Butte, M. T. Wheeler, R. Chen, T. E. Klein, F. E. Dewey, J. T. Dudley, K. E. Ormond, A. Pavlovic, A. A. Morgan, D. Pushkarev, N. F. Neff, L. Hudgins, L. Gong, L. M. Hodges, D. S. Berlin, C. F. Thorn, K. Sangkuhl, J. M. Hebert, M. Woon, H. Sagreiya, R. Whaley, J. W. Knowles, M. F. Chou, J. V. Thakuria, A. M. Rosenbaum, A. W. Zaranek, G. M. Church, H. T. Greely, S. R. Quake, and R. B. Altman. 2010. Clinical assessment incorporating a personal genome. Lancet 375(9725):1525-1535. Atherly, A. J., and D. R. Camidge. 2012. The cost-effectiveness of screening lung cancer pa- tients for targeted drug sensitivity markers. British Journal of Cancer 106(6):1100-1106. Balak, M. N., Y. Gong, G. J. Riely, R. Somwar, A. R. Li, M. F. Zakowski, A. Chiang, G. Yang, O. Ouerfelli, M. G. Kris, M. Ladanyi, V. A. Miller, and W. Pao. 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research 12(21):6494-6501. Ball, M. P., J. V. Thakuria, A. W. Zaranek, T. Clegg, A. M. Rosenbaum, X. Wu, M. Angrist, J. Bhak, J. Bobe, M. J. Callow, C. Cano, M. F. Chou, W. K. Chung, S. M. Douglas, P. W. Estep, A. Gore, P. Hulick, A. Labarga, J. H. Lee, J. E. Lunshof, B. C. Kim, J. I. Kim, Z. Li, M. F. Murray, G. B. Nilsen, B. A. Peters, A. M. Raman, H. Y. Rienhoff, K. Robasky, M. T. Wheeler, W. Vandewege, D. B. Vorhaus, J. L. Yang, L. Yang, J. Aach, E. A. Ashley, R. Drmanac, S. J. Kim, J. B. Li, L. Peshkin, C. E. Seidman, J. S. Seo, K. Zhang, H. L. Rehm, and G. M. Church. 2012. A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America 109(30):11920-11927. Basu, A., and D. Meltzer. 2007. Value of information on preference heterogeneity and indi- vidualized care. Medical Decision Making 27(2):112-127. 73

OCR for page 73
74 THE ECONOMICS OF GENOMIC MEDICINE Bean, J., G. J. Riely, M. Balak, J. L. Marks, M. Ladanyi, V. A. Miller, and W. Pao. 2008. Ac- quired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research 14(22):7519-7525. Beckman, M. G., W. C. Hooper, S. E. Critchley, and T. L. Ortel. 2010. Venous thrombo- embolism: A public health concern. American Journal of Preventive Medicine 38(4 Suppl):S495-S501. Bradbury, P. A., D. Tu, L. Seymour, P. K. Isogai, L. Zhu, R. Ng, N. Mittmann, M. S. Tsao, W. K. Evans, F. A. Shepherd, N. B. Leighl, and the NCIC Clinical Trials Working Group on Economic Analysis. 2010. Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small-cell lung cancer. Journal of the National Cancer Institute 102(5):298-306. Bristol-Myers Squibb. 2010. Prescribing information for Coumadin (warfarin sodium). Princeton, NJ: Bristol-Myers Squibb. http://www.accessdata.fda.gov/drugsatfda_docs/ label/2010/009218s108lbl.pdf (accessed March 19, 2013). Dentali, F., A. P. Sironi, W. Ageno, S. Turato, C. Bonfanti, F. Frattini, S. Crestani, and M. Franchini. 2012. Non-O blood type is the commonest genetic risk factor for VTE: Re- sults from a meta-analysis of the literature. Seminars in Thrombosis and Hemostasis 38(5):535-548. Dewey, F. E., R. Chen, S. P. Cordero, K. E. Ormond, C. Caleshu, K. J. Karczewski, M. Whirl- Carrillo, M. T. Wheeler, J. T. Dudley, J. K. Byrnes, O. E. Cornejo, J. W. Knowles, M. Woon, K. Sangkuhl, L. Gong, C. F. Thorn, J. M. Hebert, E. Capriotti, S. P. David, A. Pavlovic, A. West, J. V. Thakuria, M. P. Ball, A. W. Zaranek, H. L. Rehm, G. M. Church, J. S. West, C. D. Bustamante, M. Snyder, R. B. Altman, T. E. Klein, A. J. Butte, and E. A. Ashley. 2011. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genetics 7(9):e1002280. Epstein, R. S., T. P. Moyer, R. E. Aubert, D. J. O’Kane, F. Xia, R. R. Verbrugge, B. F. Gage, and J. R. Teagarden. 2010. Warfarin genotyping reduces hospitalization rates: Results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). Journal of the American College of Cardiology 55(25):2804-2812. Flowers, C. R., and D. Veenstra. 2004. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22(8):481-493. Grody, W. W., J. H. Griffin, A. K. Taylor, B. R. Korf, J. A. Heit, and the American College of Medical Genetics Factor V Working Group. 2001. American College of Medical Ge- netics consensus statement on Factor V Leiden mutation testing. Genetics in Medicine 3(2):139-148. Grosse, S. D., S. Wordsworth, and K. Payne. 2008. Economic methods for valuing the outcomes of genetic testing: Beyond cost-effectiveness analysis. Genetics in Medicine 10(9):648-654. Hampel, H., W. L. Frankel, E. Martin, M. Arnold, K. Khanduja, P. Kuebler, M. Clendenning, K. Sotamaa, T. Prior, J. A. Westman, J. Panescu, D. Fix, J. Lockman, J. LaJeunesse, I. Comeras, and A. de la Chapelle. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology 26(35):5783-5788. Jick, H., D. Slone, B. Westerholm, W. H. Inman, M. P. Vessey, S. Shapiro, G. P. Lewis, and J. Worcester. 1969. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1(7594):539-542. Kelly, K., J. Crowley, P. A. Bunn, Jr., C. A. Presant, P. K. Grevstad, C. M. Moinpour, S. D. Ramsey, A. J. Wozniak, G. R. Weiss, D. F. Moore, V. K. Israel, R. B. Livingston, and D. R. Gandara. 2001. Randomized phase III trial of paclitaxel plus carboplatin versus vinorel- bine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. Journal of Clinical Oncology 19(13):3210-3218.

OCR for page 73
REFERENCES 75 Kris, M. G., R. B. Natale, R. S. Herbst, T. J. Lynch, Jr., D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. S. Albain, D. Cella, M. K. Wolf, S. D. Averbuch, J. J. Ochs, and A. C. Kay. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. Journal of the American Medical Association 290(16):2149-2158. Ladabaum, U., G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin, and K. A. Phillips. 2011. Strategies to identify the Lynch syndrome among pa- tients with colorectal cancer: A cost-effectiveness analysis. Annals of Internal Medicine 155(2):69-79. Lockwood, C., G. Wendel, and Committee on Practice Bulletins—Obstetrics. 2011. Practice bulletin no. 124: Inherited thrombophilias in pregnancy. Obstetrics and Gynecology 118(3):730-740. Mallal, S., E. Phillips, G. Carosi, J. M. Molina, C. Workman, J. Tomazic, E. Jagel-Guedes, S. Rugina, O. Kozyrev, J. F. Cid, P. Hay, D. Nolan, S. Hughes, A. Hughes, S. Ryan, N. Fitch, D. Thorborn, A. Benbow, and PREDICT-1 Study Team. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine 358(6):568-579. Maron, B. J., M. S. Maron, and C. Semsarian. 2012. Genetics of hypertrophic cardiomyopa- thy after 20 years: Clinical perspectives. Journal of the American College of Cardiology 60(8):705-715. Martin, J. A., B. E. Hamilton, S. J. Ventura, M. J. Osterman, E. C. Wilson, and T. J. Mathews. 2012. Births: Final data for 2010. Atlanta, GA: Centers for Disease Control and Prevention. Medalie, J. H., C. Levene, C. Papier, U. Goldbourt, F. Dreyfuss, D. Oron, H. Neufeld, and E. Riss. 1971. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. New England Journal of Medicine 285(24):1348-1353. Mok, T. S., Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, and M. Fukuoka. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 361(10):947-957. Neel, J. V. 1949. The inheritance of sickle cell anemia. Science 110(2846):64-66. Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus. 2004. EGF receptor gene mutations are common in lung cancers from “never smokers” and are as- sociated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America 101(36):13306-13311. Pauling, L., H. A. Itano, S. J. Singer, and I. C. Wells. 1949. Sickle cell anemia: A molecular disease. Science 110(2865):543-548. Plevritis, S. K., A. W. Kurian, B. M. Sigal, B. L. Daniel, D. M. Ikeda, F. E. Stockdale, and A. M. Garber. 2006. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Journal of the American Medical Association 295(20):2374-2384. Ramsey, S. D., D. L. Veenstra, L. P. Garrison, Jr., R. Carlson, P. Billings, J. Carlson, and S. D. Sullivan. 2006. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. American Journal of Managed Care 12(4):197-202. Regier, D. A., J. M. Friedman, N. Makela, M. Ryan, and C. A. Marra. 2009. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: Willingness to pay from families of affected children. Clinical Genetics 75(6):514-521.

OCR for page 73
76 THE ECONOMICS OF GENOMIC MEDICINE Riess, J. W., and H. A. Wakelee. 2012. Metastatic non-small-cell lung cancer management: Novel targets and recent clinical advances. Clinical Advances in Hematology and Oncol- ogy 10(4):226-234. Roach, J. C., G. Glusman, A. F. Smit, C. D. Huff, R. Hubley, P. T. Shannon, L. Rowen, K. P. Pant, N. Goodman, M. Bamshad, J. Shendure, R. Drmanac, L. B. Jorde, L. Hood, and D. J. Galas. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328(5978):636-639. Russell, R. B., N. S. Green, C. A. Steiner, S. Meikle, J. L. Howse, K. Poschman, T. Dias, L. Potetz, M. J. Davidoff, K. Damus, and J. R. Petrini. 2007. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 120(1):e1-e9. Schiller, J. H., D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, D. H. Johnson, and the Eastern Cooperative Oncology Group. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 346(2):92-98. Shah, N. R., and M. B. Bracken. 2000. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. American Journal of Obstetrics and Gynecology 182(2):465-472. Shiffman, D., K. Slawsky, L. Fusfeld, J. J. Devlin, and T. F. Goss. 2012. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clinical Therapeutics 34(6):1387-1394. Silverstein, M. D., J. A. Heit, D. N. Mohr, T. M. Petterson, W. M. O’Fallon, and L. J. Melton III. 1998. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Archives of Internal Medicine 158(6):585-593. Sode, B. F., K. H. Allin, M. Dahl, F. Gyntelberg, and B. G. Nordestgaard. 2013. Risk of venous thromboembolism and myocardial infarction associated with Factor V Leiden and prothrombin mutations and blood type. Canadian Medical Association Journal 185(5):E229-E237. Srinivasan, B. S., E. A. Evans, J. Flannick, A. S. Patterson, C. C. Chang, T. Pham, S. Young, A. Kaushal, J. Lee, J. L. Jacobson, and P. Patrizio. 2010. A universal carrier test for the long tail of Mendelian disease. Reproductive Biomedicine Online 21(4):537-551. Vandenbroucke, J. P., J. Rosing, K. W. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal. 2001. Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine 344(20):1527-1535. Wang, X., B. Zuckerman, C. Pearson, G. Kaufman, C. Chen, G. Wang, T. Niu, P. H. Wise, H. Bauchner, and X. Xu. 2002. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. Journal of the American Medical Association 287(2):195-202.